Climb Bio Presents Initial PrisMN Phase 2 Data from Budoprutug in pMN at an Oral Session at ASN Kidney Week 2026GlobeNewsWire · 15 hr ago
Climb Bio and Mabworks Announce CLYM116/MIL116 Data Demonstrating Deep, Durable APRIL Suppression and ~70% Gd-IgA1 Reduction at ASN Kidney Week 2026GlobeNewsWire · 1 day ago
Are Medical Stocks Lagging Climb Bio, Inc. (CLYM) This Year?Zacks Investment Research · 5 days ago
Climb Bio: Others Proved APRIL Works, So The Bet Is On The 12-Week Dosing IntervalSeeking Alpha · Oct 7, 2026
Climb Bio to Present New Data at American Society of Nephrology (ASN) Kidney Week 2026 for CLYM116 and BudoprutugGlobeNewsWire · Oct 2, 2026
Climb Bio Phase I Data Backs 12-Week Dosing Plan for IgA Nephropathy DrugMarketBeat · Sep 3, 2026Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic solutions for inflammatory diseases driven by autoimmune responses. Its primary investigational asset is budoprutug, an anti-CD19 monoclonal antibody. This treatment is being advanced for a range of autoimmune conditions, including systemic lupus erythematosus, lupus nephritis, immune thrombocytopenia, and membranous nephropathy.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 6, 2026 | -$0.21 | -$0.18 | Beat |
| May 7, 2026 | -$0.26 | -$0.20 | Beat |
| Mar 5, 2026 | -$0.20 | -$0.26 | Miss |
| Nov 6, 2025 | -$0.16 | -$0.19 | Miss |
| Aug 12, 2025 | -$0.19 | -$0.13 | Beat |
| May 14, 2025 | -$0.15 | -$0.31 | Miss |